Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study
{{output}}
Introduction: Rapid increased utilization of GLP-1s by US patients has raised safety concerns, in addition to challenges related to supply shortfalls starting in March 2022. ... ...
